Literature DB >> 7993803

rh-erythropoietin stimulates immature reticulocyte release in man.

A Major1, C Bauer, C Breymann, A Huch, R Huch.   

Abstract

The pharmacodynamics of single intravenous dosing with recombinant human erthropoietin (rhEPO) was investigated in eight healthy volunteers (150 U/kg, n = 2; 300 U/kg, n = 6) with respect to reticulocyte subdivisions (by fluorescence flow cytometry) and serum ferritin over 6.5 d. The present study shows that bolus rhEPO injection produces an immediate release of high and middle fluorescence (immature) reticulocytes with a high RNA content from the marrow into the circulation, whereas the low fluorescence (more mature) reticulocytes were at first not affected. Serum ferritin decreased markedly within 24 h, reaching a nadir 50% of baseline after 120 h (5 d), with no increase in haemoglobin. Our data suggests that rhEPO triggers premature expulsion of immature reticulocytes from the bone marrow into the circulation independent of its effect in stimulating erythropoiesis and that rhEPO has an effect on serum ferritin concentration which in this dynamic situation is dependent not only on the iron stores.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993803     DOI: 10.1111/j.1365-2141.1994.tb08320.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

3.  Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.

Authors:  Juan José Pérez-Ruixo; Wojciech Krzyzanski; Jeremy Hing
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2007-02-21       Impact factor: 4.200

5.  Red Blood Cell Distribution Width is Associated with Poor Clinical Outcome After Subarachnoid Hemorrhage: A Pilot Study.

Authors:  C Chugh; S C Nyirjesy; K P Nawalinski; D K Sandsmark; S Frangos; E Maloney-Wilensky; S C Stein; J M Levine; S E Kasner; M A Kumar
Journal:  Neurocrit Care       Date:  2015-10       Impact factor: 3.210

Review 6.  Altitude and Erythropoietin: Comparative Evaluation of Their Impact on Key Parameters of the Athlete Biological Passport: A Review.

Authors:  Jonas J Saugy; Tania Schmoutz; Francesco Botrè
Journal:  Front Sports Act Living       Date:  2022-06-30

7.  Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Authors:  Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

8.  Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.

Authors:  Xiaoyu Yan; Sihem Ait-Oudhia; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2012-11-28       Impact factor: 4.200

9.  A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM.

Authors:  Gledys Reynaldo; Leyanis Rodríguez; Roberto Menéndez; Joaquín Solazábal; Daniel Amaro; María de Los A Becquer; Yamila Colom; Haydee Gil; Juan C Polo; Gilberto Castañeda; Braulio Jiménez-Vélez; Jorge Duconge; Eduardo M Fernández-Sánchez
Journal:  J Pharm Pharmacogn Res       Date:  2018-02-23

10.  A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats.

Authors:  Ly Minh Nguyen; Zhichuan Li; Xiaoyu Yan; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-07       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.